This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study | MicrobiomeTrials
← Back to trials NCT07509450
Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study Recruiting NA INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-06-02Est. Completion: 2029-06-02
Enrollment target: 20 participantsLocations University Health Network, Toronto, Ontario, Canada Other microbiome trials you might be interested in B-cell Acute Lymphoblastic Leukemia Diffuse Large B-cell Lymphoma Burkitt Lymphoma Neuroblastoma Ewing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United States Est. completion Mar 31, 2029
Recurrent Burkitt Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements Refractory Burkitt Lymphoma
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
This phase II/III trial tests adding glofitamab to standard of care chemoimmunotherapy in patients with Burkitt and high…
Multiple Locations Est. completion Nov 1, 2033
B-All Acute Lymphoblastic Leukemia
Background:
Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat peopl…
Los Angeles, United States Est. completion Dec 31, 2026